Bio Monthly (November 2025): Micropayments for AI Scientists, Dog Longevity, Weights vs. Cardio

Highlights from the Biosphere 🌐

• Bio's network of AI Agents for scientific research and health ("BioAgents") can now process instant USDC micropayments using @CoinbaseDev x402 + Embedded Wallets, laying the groundwork for an AI-driven coordination layer where human researchers, labs and AI Scientists can directly trade scientific knowledge and labor.
• ‍Upcoming Projects on the Bio Launchpad: DogYears (dog longevity therapeutic), Holi (Weights vs. Cardio fitness trial testing brain health markers), VitaSeno (CRISPR gene-editing to eliminate zombie cells).
• Recently Launched Projects: Foxo3 (RNA therapeutic for degenerative disc disease), Neuron-Gale (targeting brain inflammation in Alzheimer’s) & Relieva (therapeutic cannabis for pain relief).
• Scientific progress in the Bio ecosystem: Cerebrum DAO advances its brain health research to placebo-controlled human trials, VITARNA gene therapy successfully tested delivery vectors for human studies, and PsyDAO funded a research proposal for a new class of MDMA prodrugs.

Payment Rails for AI Scientists

Using Coinbase's x402 protocol, BioAgents can now issue and receive payments with third-parties: human-to-agent, agent-to-agent and agent-to-lab. The ability for BioAgents to pay for services and collect revenue on their own lays the groundwork for an onchain science economy where AI Scientists can hire each other, access paywalled data, and reward contributions instantly.

Example use-cases:

• Hypothesis & Knowledge Graph Refinement: Agents pay researchers who upload valuable new data, papers and findings to an agent's knowledge graph.
• Pap-Per-Data Access: Agents host premium or proprietary datasets with fine-grained micro-billing per retrieval request.
• Pay-Per-Analysis: Agents expose computational pipelines as on-demand services.
• Agent-to-Agent Collaboration: Agents exchange computational insights with each other - e.g., Agent A (Genomics Specialist) sells preprocessed embeddings to Agent B (Drug Designer) which pays when retrieving cluster signatures.

BioAgents are agentic science machines designed to execute tasks and generate data in the R&D lifecycle. They continuously populate a knowledge graph, generate hypotheses, design experiments and help monetize discoveries. Earlier this month, the first BioAgent,@Aubrai_, a longevity AI scientist co-developed with the longevity researcher Dr. @aubreydegrey and @vitadao, processed the first x402-enabled transaction, enabling Aubrai to issue and receive payments.

➤ Watch Coinbase GTM lead @The_Shark_7 demo the integration in this video

➤ Build on the new x402-enabled BioAgent framework, test Aubrai payments on x402scan, & stay tuned for new BioAgents launched on the Bio Launchpad.

➤ Learn more about x402 & BioAgents:

New Research Projects: Dog Longevity, Gene-Editing, Brain Health & More

Upcoming DeSci projects launching on Bio:

• DogYears - Canine longevity therapeutics
• Holi - Weights vs Cardio fitness trial testing brain health markers
• VitaSeno - CRISPR gene-editing to eliminate zombie cells

Recent launches:

• Neuron-Gale - $712K USDC committed, 14.2X oversubscribed - targeting brain inflammation in Alzheimer’s (Project Roadmap)
• Foxo3 - $152K USDC committed, 1.5X oversubscribed - RNA therapeutic aimed at activating the FOXO3 longevity gene and targeting degenerative disc disease (Project Roadmap)
• Relieva - $187K USDC, 3.7x oversubscribed - therapeutic cannabis cannabis blend for pain relief

➤ Listen to last week's X Spaces featuring the founders of Foxo3 & DogYears DAO. Stay for interviews this week with the founders of Holi, VitaSeno & more.

Dive into upcoming launches on Bio 👇

Workshop: How to Fundraise with Bio

With the launch of Bio's new self-service researcher application and permissionless launches getting closer, we hosted a livestream exploring how to use Bio to fund and accelerate scientific research, featuring Bio's Chief Science Officer, @jamessinka, & Curetopia founder, @eperlste.

➤ Apply now to fund your research on Bio

➤ Watch the workshop recording to learn more about the evolving DeSci Playbook & stay tuned for the next researcher workshop with biotech investors from Compound VC.

Staking & BioXP Upgrades: Multipliers & Ecosystem Airdrops

We announced Season 2 of Bio's staking program and loyalty layer - BioXP - which introduce new mechanics that re-engineer incentives on the network, drive additional rewards to BIO stakers (veBIO holders) and incentivize sustained support for newly launched tokens:

• BIO Staking as the Foundation: Staking BIO (to generate veBIO) is now required in order to earn XP from ecosystem token staking.
• Ecosystem Airdrops: veBIO holders passively earn automatic airdrops from new token launches.
• Level Multiplier: Your veBIO balance unlocks boosted earning power up to 10X BioXP on ecosystem token staking.
• New Token Multiplier: In the first 60 days after a new ecosystem token goes live, veBIO holders earn more XP for staking the ecosystem token.
• Following the transition from Bio Season 1 to Season 2, BioXP 14-day expiration was re-activated to reduce the total BioXP in circulation; meaning, each unit of BioXP will now generate a higher token allocation in upcoming sales.

We also haven't forgotten about yappers: We're gradually expanding the Bio Creator Program, inviting community voices to earn a slice of monthly XP.  To qualify for an invite, keep pushing DeSci and share your posts in the "flex your post" topic of our Telegram/Discord.

➤ Stake BIO and ecosystem tokens on the Bio App

Learn more about BioXP Season 2 ↓

Ecosystem Updates

• Cerebrum DAO's Percepta project's clinical trial infrastructure is complete, with the first tokenized brain health supplement reaching double-blind placebo-controlled human trials soon. Their FissionBio project tested 90 compounds and identified 15 hits that block the DRP1-FIS1 interaction driving mitochondrial dysfunction, with plans to now scale to 600 compounds. Cerebrum's Transfidelity project is currently working on understanding the pathways their hit compounds need to modulate to optimize the compounds.
• VitaDAO's $VITARNA project tested two clinically relevant delivery vectors for potential human studies. Both showed strong compatibility, giving the team a green light for scale-up and translational planning. The lead researcher of VITARNA, @Mykalt45, won the Best New Drug Developer at this year's World ADC. VitaDAO's VitaSTEM project analyzed 850K+ hematopoietic stem cells from donors and identified 11 high-confidence rejuvenation targets with target prioritization powered by Scientific AI Agent @Aubrai_. VitaDAO announced Season 2 of VitaLabs, with special incentives for projects using Aubrai - apply here. Vita also hosted a community call covering VitaLabs outcomes, Aubrai IPT updates, portfolio company progress & more.
• PsyDAO approved a $30,000 funding proposal to develop a new class of MDMA prodrugs to overcome the safety limitations and regulatory hurdles of MDMA-assisted therapy, such as cardiovascular risks, neurotoxicity, and abuse potential. The research focuses on developing a unique method  to control the drug's release that could lead to a safer pharmacological profile with a more gradual onset and fewer side effects. Listen to PsyDAO's live session discussing the latest funding for MDMA prodrugs.
• Pump Science-supported project, Blue Scorpion Venom, launched in partnership with Reputable Health, a human validation study with 35 participants using the world’s only Blue Scorpion venom–based homeopathic medicine. They started the next worm experiments with DOCS becoming the new king of the pill, achieving a 80% lifespan extension. The first chemical reprogramming intervention was launched on Pump by the Reprogramming Lab & the Rapamycin Longevity Lab.
• Long COVID Labs has received WCG IRB approval for the first patient-led Long COVID registry that rewards participants with their $COVID token. They demoed their mobile app and clinical-grade wearable at Devconnect Argentina. They also submitted their iOS app for review by the App Store, featuring symptom tracking, crowdsourced treatment leaderboard, ECG integration & more.
• HairDAO spent $260K testing 60+ dutasteride delivery vehicles & released their precision dutasteride, based on their lessons. Learn more about their formulation & order here. They also did the first test of T3 + TRH combinations on any non-cancerous human tissue with the data.
• Curetopia shared the initial mouse study results on their $RAPTOR intervention, showing that a low-dose enhanced grip strength and endurance via balanced autophagy modulation, while a higher dose triggered hypothermia and immune stress. They are also soon launching their first onchain longevity biotech.
• Quantum Biology DAO hosted the first ever quantum biology hackathon, with 29 contributors coming together to develop 6 different projects exploring how quantum effects might influence living systems. They are also building an advanced "hypo-bacterioscope" to enable precise hypomagnetic field experiments on bacterial fluorescence while continuing microbial experiments under hypomagnetic conditions.
• D1ckDAO partnered up with Welshare Health to match securely stored patient profiles, validate research hypotheses, and recruit participants for clinical trials in men's health in a privacy-preserving way. They also partnered with Episteme to launch their first prediction market, powered by a @D1ckGPT hypothesis, testing whether daily Panax Ginseng can improve erectile function on par with 5mg tadalafil (Cialis). The DAO is also hosting a meetup with Binance Thailand to activate the DeSci scene in Thailand & did a live demo of D1ckGPT at Thailand Blockchain Week.
• Dog Years DAO registered their first IP-NFT for their upcoming IPT on Bio developing Follistatin Gene Therapy for Canine Arthritis and Healthspan.
• DermaDAO will soon launch their DROPS IPT on Bio developing a skin longevity serum. Sign up for the waitlist.
• SpineDAO core team member, Dr. Virginie Lafage received the 2025 Henry Farfan Recognition Award from the North American Spine Society, one of the world’s leading spine organizations. They also presented their AI suite at the SOFCOT CAOS event in Paris.
• ValleyDAO reported on the latest progress with their Cocoa Zero project at Imperial College London.
• MicroDAO shared their Q3 update, highlighting their Pathogen Catalogue.

Community Updates

• Bio Co-founder & CEO @paulkhls & Co-founder & CEO of Apeiron Investments @C_Angermayer will do a fireside chat on the Main Stage at Binance Blockchain Week exploring how AI, biotech, and crypto are converging to unlock new scientific breakthroughs and funding models. Catch it in person or tune into the livestream.

• Bio is hosting DeSci Abu Dhabi in collaboration with @Molecule_sci on December 10 at the Cleveland Clinic featuring  MIT neuroscience pioneer @eboyden3,  Dr. Axel Bouchon from Matter Neuroscience, Pro Athlete James Magnusson & many more. RSVP or Apply to speak.

• ‍BIO was listed on the perpetuals DEX Aster, with a two-week $200,000 $ASTER + $BIO trading campaign kicking off Dec 1 until Dec 15.

• BIO was listed on Bitstamp by Robinhood.
• BSCN published an article on BioAgents and x402 driving autonomous science.
• Bio's AI team wrote a review of AI benchmarks in biomedical research & are looking for endorsements on arXiv.
• The Agentic AI Against Aging Hackathon sponsored by Bio was featured in Longevity Technology.
• Bio sponsored a 25,000 $BIO prize for the Longevity Agents × Berlin Hackathon where Bio's Head of AI @AakaashMeduri hosted a workshop on how to use the open-source BioAgents framework.@DeSciNews hosted the
• Bio Ecosystem Mega Space featuring Bio, Curetopia, ValleyDAO, Cerebrum DAO, SpineDAO, & Long COVID Labs.
• DeSci Pilled, Bio's podcast, released a new episode with Biome.

Explore New DeSci projects on the Bio App

Stay updated via our Telegram, Discord & Governance forum. Follow @BioProtocolEco on X for real-time ecosystem updates.